RxDoctor Payments Data

Donald Stephens, MD

Retina Specialist · Tallmadge, OHNPI 1952304685

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $464, 5.7 times the $81 reported in 2019. That places this record below the midpoint for retina specialist clinicians in OH, where the typical reported total is $4,390.

$1,232in general payments, 2019–2025

Across 54 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$185
  • Oyster Point Pharma, Inc.$184
  • Regeneron Healthcare Solutions, Inc.$165
  • Amgen$104
  • Alcon$103
  • AbbVie$103
  • plus $388 from 12 others

What the payments were for

  • Food & beverage$1,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,232 in reported general payments places this provider in the 30th percentile of 69 retina specialist providers in Ohio.

See all retina specialist providers in Ohio

Medicare billing

Part B allowed, 2024
$733,664
Medicare patients
405
Services billed
4,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate281$10,298
TyrvayaVarenicline Tartrate13$8,272
CombiganBrimonidine Tartrate/Timolol12$3,807
Dorzolamide Hcl156$3,072
Latanoprost354$2,443
Travoprost18$1,637
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat99$1,617
Ketorolac Tromethamine47$1,349
Ofloxacin120$1,267
Timolol Maleate131$1,151
Brimonidine Tartrate61$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$184$8,27213 claims
AbbVieCombigan$103$3,80712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 69 retina specialist providers in Ohio.

Other retina specialist in Tallmadge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →